RWM
AMRX icon

Rialto Wealth Management’s Amneal Pharmaceuticals AMRX Stock Holding History

Rialto Wealth Management’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.3K Buy
133
+118
+787% +$1.62K ﹤0.01% 1068
2026
Q1 		$187 Buy
15
+1
+7% +$13 ﹤0.01% 1609
2025
Q4 		$177 Hold
14
– – ﹤0.01% 1544
2025
Q3 		$141 Buy
14
+11
+367% +$99 ﹤0.01% 1557
2025
Q2 		$25 Buy
+3
New +$23 ﹤0.01% 1679

Other funds holding AMRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Rialto Wealth Management's AMRX Position: Q2 2026 in Review

Rialto Wealth Management increased its Amneal Pharmaceuticals (AMRX) stake by 787% in Q2 2026, buying an estimated $1.62K and bringing the position to 133 shares worth $2.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1068.

Rialto Wealth Management first reported a position in AMRX in Q2 2025 and has held it in 5 quarters since. 306 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

  • Rialto Wealth Management held 133 shares of Amneal Pharmaceuticals worth $2.3K as of Q2 2026.
  • Rialto Wealth Management bought 118 Amneal Pharmaceuticals shares in Q2 2026, an estimated $1.62K.
  • Amneal Pharmaceuticals made up ﹤0.01% of Rialto Wealth Management's portfolio in Q2 2026, its #1068 holding.
  • Rialto Wealth Management first reported a position in Amneal Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • 306 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on Rialto Wealth Management's 13F filing for Q2 2026, filed 11 Aug 2026.